Speciality: Oncology
Description:
Welcome to an insightful discussion on the critical topic of Cost Burden and Burden of Hospitalization for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Patients. Esteemed experts Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja delve into the multifaceted challenges faced by patients and healthcare systems. The conversation sheds light on the financial, emotional, and logistical strains of prolonged hospitalization, recurring treatments, and the socioeconomic disparities impacting access to advanced therapies. This session is a must-watch for healthcare professionals, policymakers, and caregivers seeking to understand the real-world implications of managing R/R ALL.
In the second segment, the panel explores actionable strategies to alleviate the burden on patients and families. Dr. Singh emphasizes the importance of cost-effective treatment protocols, while Dr. Dikshit highlights innovations in outpatient care models to reduce hospitalization frequency. Dr. Jain and Dr. Baveja further discuss the role of patient advocacy, insurance reforms, and government policies in bridging gaps in care. Their collective expertise provides a comprehensive roadmap to address systemic inefficiencies and improve the quality of life for R/R ALL patients.
Concluding on a hopeful note, the experts underscore the need for collaborative efforts between clinicians, researchers, and policymakers to drive sustainable change. The discussion not only raises awareness but also inspires actionable solutions to mitigate the economic and emotional toll of R/R ALL. Viewers are encouraged to watch the full video to gain deeper insights into this pressing issue and stay tuned for future discussions featuring these thought leaders in oncology and hematology.
See More Webinars @ Hidoc Webinars
1.
Doctors say lung cancer is still the deadliest cancer, but hope is growing
2.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
3.
FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.
4.
The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.
5.
Virtual Reality Travel Reduces Cancer Pain.
1.
Clinical Decision-Making in Oligometastatic Cancer: A Case-Based Perspective
2.
Iron Homeostasis Throughout the Female Lifespan
3.
The Benefits and Side Effects of Vidaza Syndrome
4.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
5.
Exercise Rehabilitation in Hematologic Disease Survivorship
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
3.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation